ZyVersa Therapeutics Inc. (NASDAQ:ZVSA) — Stock Price
ZyVersa Therapeutics Inc. (NASDAQ:ZVSA) is currently trading at $0.11 USD, down 6.27% today. Over the past 52 weeks, shares have ranged between $0.10 and $0.27. This page tracks ZyVersa Therapeutics Inc.'s live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of ZyVersa Therapeutics Inc..
ZyVersa Therapeutics Inc. (ZVSA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ZyVersa Therapeutics Inc.'s daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
ZyVersa Therapeutics Inc. Income Statement — Revenue, Profit & Earnings by Year
ZyVersa Therapeutics Inc.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $6.93K | $10.40K | $10.40K | $10.40K | $10.40K |
| Gross Profit | $-6.93K | $-10.40K | $-10.40K | $-10.40K | $-10.40K |
| Research & Development | $1.78 Billion | $3.21 Million | $5.41 Million | $2.12 Million | $6.47 Million |
| SG&A | $7.36 Billion | $11.21 Billion | $7.61 Million | $5.58 Million | $5.36 Million |
| Total Operating Expenses | $9.13 Million | $14.41 Million | $13.82 Million | $7.70 Million | $11.83 Million |
| Operating Income | $-9.14 Billion | $-14.42 Million | $-13.83 Million | $-7.70 Million | $-11.83 Million |
| EBITDA | $-9.14 Billion | $-107.74 Million | $-14.43 Million | $-7.25 Million | $-12.16 Million |
| EBIT | $-9.14 Billion | $-107.75 Million | $-14.44 Million | $-7.26 Million | $-12.17 Million |
| Interest Expense | $269.86K | $457.00K | $427.54K | $821.37K | $516.45K |
| Income Before Tax | $-9.42 Billion | $-107.75 Million | $-14.87 Million | $-8.08 Million | $-12.68 Million |
| Income Tax Expense | $-6.75 Million | $-9.46 Million | $-745.05K | $821.37K | $516.45K |
| Net Income | $-9.41 Billion | $-98.30 Million | $-14.05 Million | $-8.08 Million | $-12.68 Million |
ZyVersa Therapeutics Inc. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ZyVersa Therapeutics Inc.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $20.60 Million | $22.11 Million | $118.51 Million | $1.13 Million | $685.57K |
| Total Current Assets | $1.72 Million | $3.35 Million | $6.36 Million | $811.78K | $339.11K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $1.53 Billion | — | — | — | — |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | $115.70K | $27.73K | $38.13K |
| Goodwill | — | $0.00 | $11.90 Million | $0.00 | — |
| Total Liabilities | $12.08 Million | $11.04 Million | $18.51 Million | $13.63 Million | $9.24 Million |
| Total Current Liabilities | $11.23 Million | $10.19 Million | $8.19 Million | $13.63 Million | $7.56 Million |
| Long-term Debt | — | — | — | — | $1.69 Million |
| Net Debt | $-1.53 Million | $-3.13 Million | $-5.79 Million | $8.82 Million | $3.64 Million |
| Total Stockholder Equity | $8.52 Million | $11.07 Million | $99.99 Million | $-12.50 Million | $-8.56 Million |
| Retained Earnings | $-112.63 Million | $-103.22 Million | $-4.92 Million | $-52.90 Million | $-44.81 Million |
ZyVersa Therapeutics Inc. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ZyVersa Therapeutics Inc. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-7.56 Million | $-8.72 Million | $-4.89 Million | $-5.08 Million | $-5.11 Million |
| Capital Expenditures | $3.00 | $1.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-7.56 Million | $-8.72 Million | $-1.49 Million | $-5.08 Million | $-5.11 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | $5.95 Million | $5.96 Million | $1.87 Million | $5.23 Million | $4.56 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $705.57K | $1.19 Million | $3.52 Million | $4.14 Million | $3.83 Million |
| Depreciation | $6.93K | $10.40K | $9.87K | $10.40K | $10.40K |
| Change in Cash | $-1.61 Million | $-2.76 Million | $5.57 Million | $153.91K | $-549.76K |
ZyVersa Therapeutics Inc. Earnings History — EPS Actual vs. Analyst Estimates
Track ZyVersa Therapeutics Inc.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 13, 2025 | — | -0.25 | — |
| Aug 13, 2025 | -0.46 | -0.40 | -15.00% |
| May 12, 2025 | -0.73 | -0.40 | -82.50% |
| Mar 27, 2025 | -1.31 | — | — |
| Nov 14, 2024 | -2.43 | -1.60 | -51.88% |
| Aug 12, 2024 | -3.31 | -3.75 | +11.73% |
| May 15, 2024 | -4.53 | -3.70 | -22.43% |
| Mar 25, 2024 | -13.68 | -2.14 | -539.25% |